ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

被引：0
|
作者：
J. A. Kyte
A. Røssevold
R. S. Falk
B. Naume
机构：
[1] Oslo University Hospital,Department of Clinical Cancer Research
[2] Oslo University Hospital,Department of Cancer Immunology
[3] Oslo University Hospital,Department of Oncology
[4] Oslo University Hospital,Oslo Centre for Biostatistics and Epidemiology
[5] University of Oslo,Institute of Clinical Medicine
来源：
Journal of Translational Medicine | / 18卷
关键词：
Breast cancer; Triple negative; Immunotherapy; Checkpoint inhibitor; Immunogenic cell death; PD-1; PD-L1; Anthracycline; Cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
    Kyte, J. A.
    Rossevold, A.
    Falk, R. S.
    Naume, B.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [2] Results From ALICE: Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 9
  • [3] Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial
    Kyte, Jon Amund
    Rossevold, Andreas H.
    Andresen, Nikolai K.
    Bjerre, Christina Annette
    Gilje, Bjornar
    Jakobsen, Erik Hugger
    Raj, Sunil Xavier
    Falk, Ragnhild Sorum
    Borgen, Elin
    Jahr, Thea
    Garred, Oystein
    Lomo, Jon
    Mathiesen, Randi Margit
    Naume, Bjorn
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
    Dieras, V.
    Campone, M.
    Yardley, D. A.
    Romieu, G.
    Valero, V.
    Isakoff, S. J.
    Koeppen, H.
    Wilson, T. R.
    Xiao, Y.
    Shames, D. S.
    Mocci, S.
    Chen, M.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1904 - 1910
  • [5] Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
    Wang, Cheng
    Yuan, Long
    Wu, Xiujuan
    Wang, Yan
    Tian, Hao
    Zhang, Guozhi
    Wan, Andi
    Xiong, Siyi
    Wang, Chengfang
    Zhou, Yuqin
    Ma, Dandan
    Bao, Yangqiu
    Qu, Man
    Jiang, Jun
    Zhang, Yi
    Qi, Xiaowei
    BMC MEDICINE, 2024, 22 (01):
  • [6] Phase I study combining ipatasertib with chemotherapy and atezolizumab in patients with metastatic triple negative breast cancer
    Yuan, Yuan
    Yost, Susan E.
    Lee, Jin Sun
    Frankel, Paul H.
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Waisman, James
    Patel, Niki
    Sedrak, Mina
    Stewart, Daphne
    Lavasani, Sayeh
    Mortimer, Joanne
    CANCER RESEARCH, 2021, 81 (04)
  • [7] Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
    Tolaney, Sara M.
    Ziehr, David R.
    Guo, Hao
    Ng, Mei R.
    Barry, William T.
    Higgins, Michaela J.
    Isakoff, Steven J.
    Brock, Jane E.
    Ivanova, Elena V.
    Paweletz, Cloud P.
    Demeo, Michelle K.
    Ramaiya, Nikhil H.
    Overmoyer, Beth A.
    Jain, Rakesh K.
    Winer, Eric P.
    Duda, Dan G.
    ONCOLOGIST, 2017, 22 (01): : 25 - 32
  • [8] Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Alimohammadi, Mina
    Faramarzi, Fatemeh
    Mafi, Alireza
    Mousavi, Tahoora
    Rahimi, Ali
    Mirzaei, Hamed
    Asemi, Zatollah
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (31) : 2461 - 2476
  • [9] BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
    Schmid, P.
    Salvador Bofill, J.
    Bermejo, B.
    Phillips, M.
    Wheatley, D.
    Neus, F.
    Schem, C.
    Stradella, A.
    Mele, M.
    Cortes Salgado, A.
    Quiroga, V.
    Anton Torres, A.
    Llombart Cussac, A.
    Zamora, E.
    Viale, G.
    Kuemmel, S.
    Prendergast, A.
    Mousa, K.
    Gluz, O.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S411 - S412
  • [10] Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
    Rossevold, Andreas Hagen
    Andresen, Nikolai Kragoe
    Bjerre, Christina Annette
    Gilje, Bjornar
    Jakobsen, Erik Hugger
    Raj, Sunil Xavier
    Falk, Ragnhild Sorum
    Russnes, Hege Giercksky
    Jahr, Thea
    Mathiesen, Randi Ruud
    Lomo, Jon
    Garred, Oystein
    Chauhan, Sudhir Kumar
    Lereim, Ragnhild Reehorst
    Dunn, Claire
    Naume, Bjorn
    Kyte, Jon Amund
    NATURE MEDICINE, 2022, 28 (12) : 2573 - +
12345